Sulfotransferase 1A1 Arg213His polymorphism and prostate cancer risk

Arslan,Serdal; Silig,Yavuz; Pinarbasi,Hatice

doi:10.3892/etm.2011.334

Sulfotransferase 1A1 Arg213His polymorphism and prostate cancer risk

Authors:
- Serdal Arslan
- Yavuz Silig
- Hatice Pinarbasi
View Affiliations

Affiliations: Department of Molecular Biology and Genetics, Faculty of Science, Cumhuriyet University, 58140 Sivas, Turkey, Department of Biochemistry, Faculty of Medicine, Cumhuriyet University, 58140 Sivas, Turkey
Published online on: August 12, 2011 https://doi.org/10.3892/etm.2011.334
Pages: 1159-1162

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sulfotransferase 1A1 (SULT1A1) is a member of the sulfotransferase family that plays an important role in the biotransformation of numerous carcinogenic and mutagenic compounds through sulfation. A transition, G to A at position 638, in the SULT1A1 gene, results in the Arg213His change. This single nucleotide polymorphism reduces the activity and thermostability of the SULT1A1 enzyme. In the present study, the relationship between the SULT1A1 Arg213His polymorphism and prostate cancer was investigated using PCR-RFLP. No significant difference in genotype and allele distribution was noted between the prostate cancer and control populations (P=0.072; P=0.099, respectively). The risk of prostate cancer in individuals carrying the SULT1A1*2 allele (His213 allele) was determined by combining the SULT1A1*1/SULT1A1*2 (Arg/His213) and SULT1A1*2/SULT1A1*2 (His/His213) genotypes. No association was observed between SULT1A1 Arg213His polymorphism and prostate cancer incidence (P=0.24; OR, 1.36; 95% CI, 0.84-2.25). However, the His213 allele was found to increase the risk of prostate cancer by 1.36-fold. In smoker and non-smoker populations, no significant relationship was determined between the prostate cancer and control population (P=0.45; P=0.34, respectively).

View Figures

View References

1	Falany CN: Enzymology of human cytosolic sulfotransferases. FASEB J. 11:206–216. 1997.PubMed/NCBI
2	Glatt H, Engelke CE, Pabel U, Teubner W, Jones AL, Coughtrie MW, Andrae U, Falany CN and Meinl W: Sulfotransferases: genetics and role in toxicology. Toxicol Lett. 112:341–348. 2000. View Article : Google Scholar
3	Richard K, Hume R, Kaptein E, Stanley EL, Visser TJ and Coughtrie MW: Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain. J Clin Endocrinol Metab. 86:2734–2742. 2001.
4	Blanchard RL, Freimuth RR, Buck J, Weinshilboum RM and Coughtrie MW: A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily. Pharmacogenetics. 14:199–211. 2004. View Article : Google Scholar : PubMed/NCBI
5	Raftogianis RB, Wood TC, Otterness DM, Van Loon JA and Weinshilboum RM: Phenol sulfotransferase pharmacogenetics in human: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun. 239:298–304. 1997. View Article : Google Scholar : PubMed/NCBI
6	Nowell S, Ambrosone CB, Ozawa S, MacLeod SL, Mrackova G, Williams S, Plaxco J, Kadlubar FF and Lang NP: Relationship of phenol sulfotransferase activity (SULT1A1) genotype to sulfotransferase phenotype in platelet cytosol. Pharmacogenetics. 10:789–797. 2000. View Article : Google Scholar : PubMed/NCBI
7	National Cancer Institute: Annual Report to the Nation Finds Declines in Cancer Incidence and Death Rates; Special Feature Reveals Wide Variations in Lung Cancer Trends across States. https://www.cancer.gov/newscenter/pressreleases/2008/reportnation2008release.
8	Dearnaley DP: Cancer of the prostate. BMJ. 308:780–784. 1994.Erratum in: BMJ 308: 975, 1994.
9	Bamber DE, Fryer AA, Strange RC, Elder JB, Deakin M, Rajagopal R, Fawole A, Gilissen RA, Campbell FC and Coughtrie MW: Phenol sulfotransferase SUL1A1^*1 genotype is associated with reduced risk of colorectal cancer. Pharmacogenetics. 11:679–685. 2001.
10	Boccia S, Persiani R, La Torre G, Rausei S, Arzani D, Gianfagna F, Romano-Spica V, D’Ugo D and Ricciardi G: Sulfotransferase 1A1 polymorphism and gastric cancer risk: a pilot case-control study. Cancer Lett. 229:235–243. 2005. View Article : Google Scholar : PubMed/NCBI
11	Nowell S, Ratnasinghe DL, Ambrosone CB, Williams S, Teague-Ross T, Trimble L, Runnels G, Carrol A, Green B, Stone A, Johnson D, Greene G, Kadlubar FF and Lang NP: Association of SULT1A1 phenotype and genotype with prostate cancer risk in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev. 13:270–276. 2004. View Article : Google Scholar : PubMed/NCBI
12	Peng CT, Chen JC, Yeh KT, Wang YF, Hou MF, Lee TP, Shih MC, Chang JY and Chang JG: The relationship among the polymorphisms of SULT1A1, 1A2 and different types of cancers in Taiwanese. Int J Mol Med. 11:85–89. 2003.PubMed/NCBI
13	Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, Garber JE, Haber DA and Polyak K: Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res. 60:6859–6863. 2000.PubMed/NCBI
14	Silig Y, Pinarbası H, Güneş S, Ayan S, Bagci H and Çetinkaya Ö: Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in Turkish population. Cancer Invest. 24:41–45. 2006. View Article : Google Scholar : PubMed/NCBI
15	Steiner M, Bastian M, Schulz WA, Pulte T, Franke KH, Röhring A, Wolff JM, Seiter H and Schuff-Werner P: Phenol sulphotransferase SULT1A1 polymorphism in prostate cancer: lack of association. Arch Toxicol. 74:222–225. 2000. View Article : Google Scholar : PubMed/NCBI
16	Zheng W, Xie D, Cerhan JR, Sellers TA, Wen W and Folsom AR: Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat-intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 10:89–94. 2001.PubMed/NCBI
17	Sambrook J, Fritsch E and Maniatis T: Molecular Cloning A Laboratory Manual. 2nd edition. Cold Spring Harbor Laboratory Press; Plainview: 1989
18	Wormhoudt LW, Commandeur JN and Vermeulen NP: Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol. 29:59–124. 1999. View Article : Google Scholar
19	Coughtrie MW, Gilissen RA, Shek B, Strange RC, Fryer AA, Jones PW and Bamber DE: Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J. 337:45–49. 1999. View Article : Google Scholar : PubMed/NCBI
20	Arslan S, Siliğ Y and Pınarbaşı H: An investigation of the relationship between SULT1A1 Arg²¹³His polymorphism and lung cancer susceptibility in a Turkish population. Cell Biochem Funct. 27:1–5. 2009. View Article : Google Scholar : PubMed/NCBI
21	Kim KA, Lee SY, Park PW, Ha JM and Park JY: Genetic polymorphisms and linkage disequilibrium of sulfotransferase SULT1A1 and SULT1A2 in a Korean population: comparison of other ethnic groups. Eur J Clin Pharmacol. 61:743–747. 2005. View Article : Google Scholar : PubMed/NCBI
22	Bardakci F, Arslan S, Bardakci S, Binatli AO and Budak M: Sulfotransferase 1A1 (SULT1A1) polymorphism and susceptibility to primary brain tumors. J Cancer Res Clin Oncol. 134:109–114. 2008. View Article : Google Scholar : PubMed/NCBI
23	Banoglu E: Current status of the cytosolic sulfotransferases in the metabolic activation of promutagens and procarcinogens. Curr Drug Metab. 1:1–30. 2000. View Article : Google Scholar : PubMed/NCBI
24	Shirai T, Tamano S, Sano M, Masui T, Hasegawa R and Ito N: Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP) in rats: dose-response studies. Princess Takamatsu Symp. 23:232–239. 1995.
25	Chou HC, Lang NP and Kadlubar FF: Metabolic activation of the N-hydroxy derivative of the carcinogen 4-aminobiphenyl by human tissue sulfotransferases. Carcinogenesis. 16:413–417. 1995. View Article : Google Scholar : PubMed/NCBI
26	Ozawa S, Chou HC, Kadlubar FF, Nagata K, Yamazoe Y and Kato R: Activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b] pyridine by cDNA-expressed human and rat arylsulfotransferases. Jpn J Cancer Res. 85:1220–1228. 1994.